AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24076487
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 110 mg bid
Trial: 24076487
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg bid
Trial: 22713948
Drug: Morphine (0.1mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1mg/kg I/M)
Trial: 17851042
Drug: 5 to
RxNorm normalized name: Hy5 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 to 20 mg/d of oral olanzapine
Trial: 15983892
Drug: Multi-drug therapies
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug therapies containing zidovudine, stavudine, or other combinations
Trial: 8829023
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of pravastatin
Trial: 8829023
Drug: 500 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/d of probucol and 600 mg/d of pantethine
Trial: 8829023
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus exercise therapy
Trial: 29692290
Drug: Interviewer‐administered NVS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer‐administered NVS
Trial: 22311405
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM) with Qinggan Lidan Decoction (QLD) during icteric stage and Yigan Jiangmei Decoction (YJD) in non-icteric hyper-aminotransferase stage, alongside Ganciclovir 5 mg/kg every 12 hours for 2 weeks, then 5 mg/kg once a day for 5 days every week for 8 weeks
Trial: 22311405
Drug: Ganciclovir 5
RxNorm normalized name: ganciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 5 mg/kg every 12 hours for 2 weeks, then 5 mg/kg once a day for 5 days every week for 8 weeks, with glucurolactone 50 mg three times per day
Trial: 17618525
Drug: Ropinirole (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (0.75 to 15.0 mg/day, mean dose 7.12 mg/day)
Trial: 16287635
Drug: Dance movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance movement therapy (DMT)
Trial: 12161482
Drug: Raloxifene 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 180 mg/d
Trial: 10334649
Drug: 10 mmol/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mmol/d Mg supplement as Mg(OH)2 (approximately 22 mmol Mg/d) for 28 d
Trial: 10334649
Drug: Self-selected diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected diet (approximately 11 mmol Mg/d)
Trial: 8611062
Drug: Ethanol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.25 g/kg
Trial: 8026301
Drug: Ethanol 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.50 g/kg
Trial: 8026301
Drug: Ethanol 0.75
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.75 g/kg
Trial: 8611062
Drug: Ethanol 0
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0 g/kg (Control)
Trial: 8611062
Drug: Ethanol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (all doses)
Trial: 29364063
Drug: 7.5% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% sucrose solution (CHO)
Trial: 29364063
Drug: Flavour and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavour and taste matched placebo solution (PLA)
Trial: 23001190
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of melatonin taken 11 h before baseline sleep midpoint, then 1 h earlier on subsequent days
Trial: 21600325
Drug: PTH (1‐34)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH (1‐34) treatment
Trial: 17163236
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate treatment in RA patients
Trial: 17163236
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate treatment in PsA patients
Trial: 11139949
Drug: Sotalol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (320 +/- 20 mg/day)
Trial: 11139949
Drug: Propafenone (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (450 mg/day)
Trial: 27444494
Drug: Cyclizine 50
RxNorm normalized name: cyclizine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclizine 50 mg (test)
Trial: 27444494
Drug: Valoid 50
RxNorm normalized name: Valoid 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valoid 50 mg (reference)
Trial: 24002927
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of risedronate sodium 35 mg
Trial: 24002927
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of risedronate sodium 35 mg
Trial: 18641105
Drug: 6.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg/kg fospropofol
Trial: 18641105
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg fospropofol
Trial: 14689224
Drug: Intrarectal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal instillation of lidocaine-prilocain cream (n=75)
Trial: 14689224
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with sonographic gel intrarectally (n=40)
Trial: 9376574
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 10 microg/kg/d filgrastim and 20 microg/kg/d SCF for 7 days
Trial: 9376574
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 10 microg/kg/d filgrastim and 25 microg/kg/d SCF for 7 days
Trial: 31657712
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg furosemide
Trial: 29528807
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy Skills Training Group (DBTSTG)
Trial: 29528807
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy Group (CTG)
Trial: 29955803
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session)
Trial: 26956875
Drug: Compound kushen
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound kushen injection in combination with single-agent chemotherapy
Trial: 26956875
Drug: Standard platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard platinum-based doublet chemotherapy
Trial: 24607773
Drug: Dual ETA/ETB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual ETA/ETB receptor blockade
Trial: 12117361
Drug: Donepezil (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (oral administration for a 5-month period)
Trial: 9933049
Drug: Doxazosin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (titrated to doses of 2, 4, 8, or 12 mg once daily)
Trial: 836384
Drug: Resection treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resection treatment (partial duodenopancreatectomy, subtotal left pancreatic resection)
Trial: 30869165
Drug: Perampanel 2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 2, 4, 8, and 12 mg
Trial: 17472017
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (12.5 mg hydrochlorothiazide + 5 mg felodipine)
Trial: 17472017
Drug: Monotherapy (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (12.5 mg hydrochlorothiazide + placebo)
Trial: 15703092
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (10 ml periprostatic)
Trial: 15703092
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (10 ml periprostatic)
Trial: 8198930
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg day-1
Trial: 8198930
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg day-1
Trial: 2836565
Drug: CP at
RxNorm normalized name: GLYCERYL ACRYLATE/ACRYLIC ACID COPOLYMER (300000 CP AT 2%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP at 120 mg/m2 over one hour on day 1, plus fluorouracil (5‐FU) at 1,000 mg/m2 over 24 hours as a continuous infusion on days 1 through 5
Trial: 2836565
Drug: CP/5‐FU as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP/5‐FU as in A, plus DDTC at 600 mg/m2 over 30 minutes administered IV exactly 30 minutes after CP infusion, plus DDTC at 200 mg/m2 administered IV over 30 minutes on days 8 and 15
Trial: 29876770
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (pantoprazole capsules, 40 mg)
Trial: 29876770
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (pantoprazole tablets, 40 mg)
Trial: 29876770
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (lansoprazole, 30 mg)
Trial: 29876770
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (esomeprazole, 20 mg)
Trial: 29876770
Drug: Group E
RxNorm normalized name: Prostaglandin group E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E (rabeprazole, 10 mg)
Trial: 26699168
Drug: Selexipag (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag (maximum dose, 1600 μg twice daily)
Trial: 20814970
Drug: Intravenous neridronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous neridronate (100 mg infusion for 2 consecutive days)
Trial: 20814970
Drug: Intramuscular neridronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular neridronate (25 mg injection weekly for 2 months)
Trial: 11023759
Drug: Imiquimod 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 2% cream
Trial: 8828528
Drug: Optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal treatment of asthma based on the International Consensus Report on the Management of Asthma
Trial: 1405323
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (15, 50, or 150 U/kg) given intravenously every other day for four injections
Trial: 3902377
Drug: New suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New suppositories (800 mg paracetamol, 16 mg codeine phosphate, 12.5 mg buclizine hydrochloride)
Trial: 3902377
Drug: Old suppositories
RxNorm normalized name: Oldenlandia diffusa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old suppositories (800 mg paracetamol, 16 mg codeine phosphate, 12.5 mg buclizine hydrochloride)
Trial: 3902377
Drug: New suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New suppositories
Trial: 3902377
Drug: Old suppositories
RxNorm normalized name: Oldenlandia diffusa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old suppositories
Trial: 31329819
Drug: Standard Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Administration
Trial: 27919285
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (EN-PENS)
Trial: 27919285
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (sham)
Trial: 23740399
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration with sodium bicarbonate as an adjunct to 2% lignocaine and 1:80,000 adrenaline
Trial: 17418038
Drug: Progesterone (PG)
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone (PG) treatment group
Trial: 15229622
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Group D)
Trial: 11980769
Drug: Trimegestone 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimegestone 0.25 mg/day combined with continuous E(2) 2 mg/day
Trial: 11980769
Drug: Trimegestone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimegestone 0.5 mg/day
Trial: 11980769
Drug: Trimegestone 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimegestone 0.05 mg and 0.1 mg
Trial: 10431997
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (0.27 mmol/kg)
Trial: 7587856
Drug: Preprandial regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial regular insulin combined with glibenclamide (group D)
Trial: 7587856
Drug: Bedtime NPH
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime NPH insulin combined with glibenclamide (group N)
Trial: 22976655
Drug: 2-phase treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-phase treatment (Twin Block therapy followed by fixed appliance therapy with nonextraction)
Trial: 22976655
Drug: 1-phase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-phase treatment (fixed appliance therapy with extraction of 4 first premolars)
Trial: 12750665
Drug: 2-phase treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-phase treatment
Trial: 12750665
Drug: 1-phase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-phase treatment
Trial: 20210799
Drug: Whole Breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Breast Radiation Therapy (WBRT)
Trial: 15202583
Drug: Selective estrogen
RxNorm normalized name: Selective estrogen receptor modulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective estrogen receptor modifiers
Trial: 7944506
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU of oral vitamin E (alpha-tocopherol acetate)
Trial: 3225767
Drug: 5-mg immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg immediate release (IR) tablet given twice daily
Trial: 3225767
Drug: 5-mg sustained-release
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg sustained-release (SR) capsule formulations given daily
Trial: 24981319
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 200 mg subcutaneously every 2 weeks (induction dosing: 400 mg at Weeks 0, 2, and 4)
Trial: 24981319
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) monotherapy
Trial: 20974604
Drug: GW274150 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW274150 120 mg
Trial: 20974604
Drug: GW274150 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW274150 60 mg (Part 2)
Trial: 16141420
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (2 to 4 mg perindopril plus 2.0 to 2.5 mg indapamide for those without contraindications)
Trial: 11952446
Drug: Intra-articular 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular 20 mL 0.5% bupivacaine with epinephrine (B + E‐group)
Trial: 9772936
Drug: Indapamide 1.5
RxNorm normalized name: indapamide 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.5 mg sustained release
Trial: 28658026
Drug: 150 mL/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mL/min
Trial: 27063854
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg plus Solifenacin 5 mg
Trial: 25189764
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IIT) with blood glucose target between 4.4 and 6 mmol.L(‐1)
Trial: 25189764
Drug: Conventional glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose management with blood glucose target between 5.5 and 9 mmol.L(‐1)
Trial: 15099664
Drug: Buprenorphine/naloxone (32/8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (32/8 mg)
Trial: 15099664
Drug: Buprenorphine/naloxone (16/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (16/4 mg)
Trial: 15099664
Drug: Buprenorphine/naloxone (8/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (8/2 mg)
Trial: 12238830
Drug: Sotalol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (80 mg twice daily for 5 days starting from the morning of the first postoperative day)
Trial: 12238830
Drug: Magnesium (1.5
RxNorm normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (1.5 g daily for 6 days starting in the operating room just before cardiopulmonary bypass)
Trial: 12238830
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic agents (Control group)
Trial: 7696074
Drug: Edrophonium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.75 mg kg‐1 administered 5 or 10 min after mivacurium, or when T1 had recovered to 5, 10, 25 or 50% of control.
Trial: 29511807
Drug: D-amphetamine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (40 mg)
Trial: 29511807
Drug: lisdexamfetamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisdexamfetamine (100 mg)
Trial: 23939631
Drug: Sotatercept 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept 0.3 mg/kg
Trial: 26370220
Drug: Sotatercept 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept 0.5 mg/kg
Trial: 23939631
Drug: Sotatercept 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept 0.1 mg/kg
Trial: 24608361
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) 60 mg/kg
Trial: 15213033
Drug: L-Rhamnose
RxNorm normalized name: L-rhamnose isomerase
DrugBank: Rhamnose (DB02961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Rhamnose
Trial: 9681082
Drug: Dexamethasone plus
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone plus granisetron (1 mg b.d. p.o.)
Trial: 9681082
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg b.d. p.o.)
Trial: 356968
Drug: Intensive C.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive C. parvum immunotherapy
Trial: 356968
Drug: Nonintensive C.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonintensive C. parvum immunotherapy
Trial: 25975816
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg luseogliflozin + 30 mg pioglitazone
Trial: 25975816
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg luseogliflozin + 50 mg miglitol
Trial: 25975816
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg luseogliflozin + 1 mg glimepiride
Trial: 25975816
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg luseogliflozin + 250 mg metformin
Trial: 25975816
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg luseogliflozin + 50 mg sitagliptin
Trial: 25975816
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg luseogliflozin + 0.6 mg voglibose
Trial: 23118347
Drug: Control (drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (drugs with inert CYP effects)